The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy

Hu, Li-Sheng; Cao, Ziyang; Ma, Liang; Liu, Zhongqiu; Liao, Guochao; Wang, Junxia; Shen, Song; Li, Dongdong; Yang, Xianzhu

doi:10.1016/j.biomaterials.2019.119469

Cited by 115 publications

(78 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, anti‐PD‐L1 can inhibit the interaction between PD‐L1 (in tumor cells) and PD‐1 (in T‐cells), thus rescue the T cells (Figure a) . However, this kind of checkpoint blockade immunotherapy, being only effective for tumors with the presence of T‐cells, has low response rates (10–40 %) . On the other hand, as shown in Figure a, PDT can release tumor specific antigen through tumor cells apoptosis, inducing acute inflammation and increasing the infiltration of T‐cells .…”

Section: Resultsmentioning

confidence: 99%

Elucidation of the Intersystem Crossing Mechanism in a Helical BODIPY for Low‐Dose Photodynamic Therapy

et al. 2020

View full text Add to dashboard Cite

Intersystem crossing (ISC) of triplet photosensitizers is a vital process for fundamental photochemistry and photodynamic therapy (PDT). Herein, we report the co‐existence of efficient ISC and long triplet excited lifetime in a heavy atom‐free bodipy helicene molecule. Via theoretical computation and time‐resolved EPR spectroscopy, we confirmed that the ISC of the bodipy results from its twisted molecular structure and reduced symmetry. The twisted bodipy shows intense long wavelength absorption (ϵ=1.76×105 m−1 cm−1 at 630 nm), satisfactory triplet quantum yield (ΦT=52 %), and long‐lived triplet state (τT=492 μs), leading to unprecedented performance as a triplet photosensitizer for PDT. Moreover, nanoparticles constructed with such helical bodipy show efficient PDT‐mediated antitumor immunity amplification with an ultra‐low dose (0.25 μg kg−1), which is several hundred times lower than that of the existing PDT reagents.

show abstract

Section: Resultsmentioning

confidence: 99%

Elucidation of the Intersystem Crossing Mechanism in a Helical BODIPY for Low‐Dose Photodynamic Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the process of immunogenic cell necrosis, calreticulin (CRT) transfers to the cell membrane to promote the recruitment, recognition, and antigen expression of DC to strengthen the host immune response. It has been reported that some chemotherapeutic drugs (DOX, oxaliplatin) and PDT can induce immunogenic cell death (ICD) [182][183][184]. Recent studies have shown that manganese (Mn) can enhance cyclic guanosine monophosphate/adenosine monophosphate (GMP-AMP) synthase and STING activation of viral infection [185].…”

Section: Combination Therapymentioning

confidence: 99%

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Song

Liu

Chen

et al. 2021

IJMS

View full text Add to dashboard Cite

Melanoma, as a tumor cell derived from melanocyte transformation, has the characteristics of malignant proliferation, high metastasis, rapid recurrence, and a low survival rate. Traditional therapy has many shortcomings, including drug side effects and poor patient compliance, and so on. Therefore, the development of an effective treatment is necessary. Currently, nanotechnologies are a promising oncology treatment strategy because of their ability to effectively deliver drugs and other bioactive molecules to targeted tissues with low toxicity, thereby improving the clinical efficacy of cancer therapy. In this review, the application of nanotechnology in the treatment of melanoma is reviewed and discussed. First, the pathogenesis and molecular targets of melanoma are elucidated, and the current clinical treatment strategies and deficiencies of melanoma are then introduced. Following this, we discuss the main features of developing efficient nanosystems and introduce the latest reports in the literature on nanoparticles for the treatment of melanoma. Subsequently, we review and discuss the application of nanoparticles in chemotherapeutic agents, immunotherapy, mRNA vaccines, and photothermal therapy, as well as the potential of nanotechnology in the early diagnosis of melanoma.

show abstract

“…The nanoparticle surface can be modified with functional groups or targeting agents to improve biodistribution and tumor-specific uptake. A number of research groups have recently begun testing various nanoparticle-photosensitizer formulations for PDT in combination with immune checkpoint blockade against CTLA-4 (54,55) and PD-1/ PD-L1 (52,(56)(57)(58).…”

Section: Multimodal Treatment Utilizing Nanomaterialsmentioning

confidence: 99%

Photodynamic Therapy and Immune Checkpoint Blockade^†

Cramer

Moon

Cengel

et al. 2020

Photochem & Photobiology

View full text Add to dashboard Cite

Immune checkpoints including PD‐1 and CTLA‐4 help to regulate the intensity and timeframe of the immune response. Since they become upregulated in cancer and prevent sufficient antitumor immunity, monoclonal antibodies against these checkpoints have shown clinical promise for a range of cancers. Multimodal treatment plans combining immune checkpoint inhibitors with other therapies, including photodynamic therapy (PDT), may help to expand treatment efficacy and minimize side effects. PDT's cytotoxic effects are spatially limited by the light activation process, constraining PDT direct effects to the treatment field. The production of damage‐associated molecular patterns and tumor‐associated antigens from PDT can encourage accumulation and maturation of antigen‐presenting cells and reprogram the tumor microenvironment to be more susceptible to therapies targeting immune checkpoints.

show abstract

The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy

Cited by 115 publications

References 48 publications

Elucidation of the Intersystem Crossing Mechanism in a Helical BODIPY for Low‐Dose Photodynamic Therapy

Elucidation of the Intersystem Crossing Mechanism in a Helical BODIPY for Low‐Dose Photodynamic Therapy

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Photodynamic Therapy and Immune Checkpoint Blockade^†

Contact Info

Product

Resources

About

The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy

Cited by 115 publications

References 48 publications

Elucidation of the Intersystem Crossing Mechanism in a Helical BODIPY for Low‐Dose Photodynamic Therapy

Elucidation of the Intersystem Crossing Mechanism in a Helical BODIPY for Low‐Dose Photodynamic Therapy

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Photodynamic Therapy and Immune Checkpoint Blockade†

Contact Info

Product

Resources

About

Photodynamic Therapy and Immune Checkpoint Blockade^†